Moufidath Adjibade, Camille Davisse-Paturet, Amandine Divaret-Chauveau, Karine Adel-Patient, Chantal Raherison, Marie-Noëlle Dufourg, Sandrine Lioret, Marie-Aline Charles, Blandine de Lauzon-Guillain, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Développement, Adaptation et Handicap. Régulations cardio-respiratoires et de la motricité (DevAH), Université de Lorraine (UL), Service d’allergologie pédiatrique [CHRU de Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Pharmacologie et Immunoanalyse (SPI), Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Cancer environnement (EPICENE ), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Etude longitudinale française depuis l'enfance (UMS : Ined-Inserm-EFS) (ELFE), Institut national d'études démographiques (INED)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), The present study is funded by an ANR grant (InfaDiet project, grant number: ANR-19-CE36-0008).The ELFE cohort is a joint project between INED (Institut National d'Etudes Démographiques), INSERM (Institut National de la Santé et de la Recherche Médicale), EFS (Etablissement Français du Sang), InVS (Institut de Veille Sanitaire), INSEE (Institut National de la Statistique et des Etudes Economiques), the Ministry of Health (DGS, Direction Générale de la Santé), the Ministry of Environment (DGPR, Direction Générale de la Prévention des Risques), the Ministry of Health and Employment (DREES, Direction de la Recherche, des Etudes, de l'Evaluation et des Statistiques), and the CNAF (Caisse Nationale des Allocations Familiales), with the support of the Ministry of Research and CCDSHS (Comité de Concertation pour les Données en Sciences Humaines et Sociales) and the Ministry of Culture (DEPS, Département des études, de la prospective et des statistiques). As part of the RECONAI platform, the study received state funding from the ANR within the framework of the 'Future Investments' program (reference: ANR-11- EQPX-0038, ANR-19-COHO-0001)., ANR-19-CE36-0008,InfaDiet,Influence de l'alimentation infantile sur la croissance et le développement de l'enfant(2019), ANR-11-EQPX-0038,RE-CO-NAI,Plateforme de REcherche sur les COhortes d'enfants suivis depuis la NAIssance(2011), ANR-19-COHO-0001,RE-CO-NAI (COHORTES),Resarch platform on cohorts of children followed from birth(2019), Unité d'Allergologie Pédiatrique, EPICENE Team, Inserm U1219, Bordeaux Population Health Research Center, University of Bordeaux, F-33076 Bordeaux, France., de Lauzon-Guillain, Blandine, Influence de l'alimentation infantile sur la croissance et le développement de l'enfant - - InfaDiet2019 - ANR-19-CE36-0008 - AAPG2019 - VALID, Equipements d'excellence - Plateforme de REcherche sur les COhortes d'enfants suivis depuis la NAIssance - - RE-CO-NAI2011 - ANR-11-EQPX-0038 - EQPX - VALID, and Resarch platform on cohorts of children followed from birth - - RE-CO-NAI (COHORTES)2019 - ANR-19-COHO-0001 - COHO - VALID
International audience; ABSTRACT Background An increasing number of infant and follow-on formulas are enriched with probiotics and/or prebiotics; however, evidence for health effects of such enrichment in early childhood remains inconclusive. Objectives The present study aimed to assess whether the consumption of formula enriched with probiotics or prebiotics was associated with the risk of infection and allergic diseases in early childhood. Methods Analyses involved data for 8389 formula-fed children from the Etude Longitudinale Française depuis l'Enfance (ELFE) cohort. Enrichment of the formula with probiotics or prebiotics that was consumed from the age of 2–10 mo was identified by the formula ingredient list. Lower respiratory tract infection (LRTI), upper respiratory tract infection (URTI), gastrointestinal infection, wheezing, asthma, food allergy, and itchy rash were prospectively reported by parents up to the age of 5.5 y. Adjusted logistic regression models were used to assess associations between the consumption of enriched formula and risk of infection and allergic diseases. Results Aged 2 mo, more than half of formula-fed infants consumed the probiotic-enriched formula and only 1 in 10 consumed the prebiotic-enriched formula. Consumption of the Bifidobacterium lactis-enriched formula at 2 mo was associated with a lower risk of LRTI [OR (95% CI) = 0.84 (0.73–0.96)]. Consumption of the Bifidobacterium breve-enriched formula up to 6 mo was associated with a higher risk of LRTI [OR (95% CI) = 1.75 (1.29–2.38)] and asthma [OR (95% CI) = 1.95 (1.28–2.97)], whereas its consumption from 6 to 10 mo was associated with a lower risk of LRTI [OR (95% CI) = 0.64 (0.48–0.86)] and asthma [OR (95% CI) = 0.59 (0.40–0.88)]. Moreover, the consumption of Streptococcus thermophilus from 6 to 10 mo was associated with a higher risk of asthma [OR (95% CI) = 1.84 (1.29–2.63)]. No significant association was found for gastrointestinal infection, food allergy, and itchy rash. Overall, the consumption of prebiotic-enriched formula was not significantly associated with infection and allergy risk. Conclusions Associations between the consumption of probiotic-enriched formula and risk of respiratory symptoms differ according to the strain considered and consumption period. Further well-designed studies are needed to confirm these results.